- Digestive Illness Week is the most important worldwide gathering of physicians, researchers and lecturers within the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgical procedure
BERKELEY, Calif. and MAINZ, Germany, Might 09, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Firm”), a molecular genetics diagnostic firm specializing within the early detection of most cancers, introduced as we speak that it’ll convey collectively key opinion leaders (KOLs) from throughout the Colorectal Most cancers (CRC) screening and diagnostics neighborhood in an occasion to be held throughout Digestive Illness Week (DDW 2022) in San Diego, California.
“DDW is the middle of gravity for the worldwide digestive illness neighborhood and a great discussion board for us to convey collectively a gaggle of leaders of their fields to debate the long run development of colorectal most cancers diagnostics,” commented Guido Baechler, Chief Govt Officer of Mainz Biomed. “As an organization devoted to growing next-generation molecular diagnostic instruments to enhance early detection and prevention of CRC and different severe most cancers indications, it’s invaluable to have interaction with trade leaders, to share information and collectively formulate concepts which have the potential to dramatically change the lives of these dwelling with these ailments.”
Digestive Illness Week is the most important worldwide gathering of physicians, researchers and lecturers within the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgical procedure. Collectively sponsored by the American Affiliation for the Research of Liver Illnesses (AASLD), the American Gastroenterological Affiliation (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Surgical procedure of the Alimentary Tract (SSAT), DDW is an in-person and digital assembly, operating from Might 21-24, 2022. The assembly showcases greater than 5,000 abstracts and lots of of lectures on the newest advances in GI analysis, medication, and expertise.
Whereas attending DDW 2022, Mainz Biomed CEO Guido Baechler can even take part within the World Endoscopy Group’s (WEO) Colorectal Most cancers Screening Committee assembly which will likely be held on Might 20, 2022. The committee brings collectively a world community of members with the targets to offer worldwide fora for matters associated to colorectal most cancers screening and surveillance, to advertise innovation and efficient supply of colorectal most cancers screening and surveillance, and to collaborate in addressing points and gaps in colorectal most cancers screening and surveillance.
About ColoAlert
ColoAlert detects colorectal most cancers (CRC) through a simple-to-administer take a look at with a sensitivity and specificity almost as excessive because the invasive colonoscopy*. The take a look at makes use of proprietary strategies to research cell DNA for particular tumor markers mixed with the fecal immunochemical take a look at (FIT) and is designed to detect tumor DNA and CRC circumstances of their earliest levels. The product is CE-IVD marked (complying with EU security, well being and environmental necessities) and is transitioning to compliance with IVDR. The product is commercially obtainable in a choice of international locations within the European Union. Mainz Biomed presently distributes ColoAlert via a variety of medical associates. As soon as authorized within the U.S., the Firm’s business technique is to determine scalable distribution via a collaborative companion program with regional and nationwide laboratory service suppliers throughout the nation.
About Colorectal Most cancers
Colorectal most cancers (CRC) is the second most deadly most cancers within the U.S. and Europe, but in addition essentially the most preventable with early detection offering survival charges above 90%. Annual testing prices per affected person are minimal, particularly when in comparison with late-stage therapies of CRC which price sufferers a mean of $38,469 per 12 months. The American Most cancers Society estimated that in 2021 there have been roughly 149,500 new circumstances of colon and rectal most cancers within the U.S. with 52,980 leading to dying. Latest FDA choices recommend that screening with stool DNA checks resembling ColoAlert within the U.S. needs to be performed as soon as each three years beginning at age 45. At present there are 112 million Individuals aged 50+, a complete that’s anticipated to extend to 157 million inside 10 years. Appropriately testing these U.S.-based 50+ populations each three years as prescribed equates to a U.S. market alternative of roughly $3.7 Billion per 12 months.
About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular genetic diagnostic options for life-threatening situations. The Firm’s flagship product is ColoAlert, an correct, non-invasive, and easy-to-use early detection diagnostic take a look at for colorectal most cancers. ColoAlert is presently marketed throughout Europe with FDA medical research and submission course of meant to be launched within the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio consists of PancAlert, an early-stage pancreatic most cancers screening take a look at primarily based on Actual-Time Polymerase Chain Response-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick expertise, a platform being developed to detect pathogens on a molecular genetic foundation.
For extra data please go to www.mainzbiomed.com
For media enquiries, please contact press@mainzbiomed.com
For investor enquiries, please contact ir@mainzbiomed.com
Ahead-Trying Statements
Sure statements made on this press launch are “forward-looking statements” inside the that means of the “secure harbor” provisions of the Non-public Securities Litigation Reform Act of 1995. Ahead-looking statements could also be recognized by way of phrases resembling “anticipate”, “consider”, “anticipate”, “estimate”, “plan”, “outlook”, and “challenge” and different related expressions that predict or point out future occasions or traits or that aren’t statements of historic issues. These forward-looking statements replicate the present evaluation of present data and are topic to varied dangers and uncertainties. In consequence, warning have to be exercised in counting on forward-looking statements. As a result of identified and unknown dangers, precise outcomes might differ materially from the Firm’s expectations or projections. The next components, amongst others, might trigger precise outcomes to vary materially from these described in these forward-looking statements: (i) the failure to fulfill projected growth and associated targets; (ii) modifications in relevant legal guidelines or laws; (iii) the impact of the COVID-19 pandemic on the Firm and its present or meant markets; and (iv) different dangers and uncertainties described herein, in addition to these dangers and uncertainties mentioned on occasion in different studies and different public filings with the Securities and Trade Fee (the “SEC”) by the Firm. Further data regarding these and different components that will affect the Firm’s expectations and projections could be present in its preliminary filings with the SEC, together with its Prospectus filed on October 12, 2021 and amended on October 25, 2021 and November 1, 2021 in addition to the Prospectus filed on January 21, 2022. The Firm’s SEC filings can be found publicly on the SEC’s web site at www.sec.gov. Any forward-looking assertion made by us on this press launch relies solely on data presently obtainable to Mainz Biomed and speaks solely as of the date on which it’s made. Mainz Biomed undertakes no obligation to publicly replace any forward-looking assertion, whether or not written or oral, that could be made on occasion, whether or not on account of new data, future developments or in any other case, besides as required by legislation.
